Home > Publications database > Tobacco Smoking and Risk of Second Primary Lung Cancer. > print

001     167921
005     20240229133554.0
024 7 _ |a pmid:33722709
|2 pmid
024 7 _ |a 1556-0864
|2 ISSN
024 7 _ |a 1556-1380
|2 ISSN
024 7 _ |a doi:10.1016/j.jtho.2021.02.024.
|2 doi
024 7 _ |a doi:10.1016/j.jtho.2021.02.024.
|2 doi
037 _ _ |a DKFZ-2021-00640
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Aredo, Jacqueline V
|b 0
245 _ _ |a Tobacco Smoking and Risk of Second Primary Lung Cancer.
260 _ _ |a Amsterdam
|c 2021
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1625051745_24032
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 16(6):968-979
520 _ _ |a Lung cancer survivors are at high risk of a second primary lung cancer (SPLC). However, SPLC risk factors have not been established and the impact of tobacco smoking remains controversial. We examined risk factors for SPLC across multiple epidemiologic cohorts and assessed the impact of smoking cessation on reducing SPLC risk.We analyzed data from 7,059 participants in the Multiethnic Cohort (MEC) diagnosed with an initial primary lung cancer (IPLC) between 1993 and 2017. Cause-specific proportional hazards models estimated SPLC risk. We conducted validation studies using the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, N=3,423 IPLC cases) and European Prospective Investigation into Cancer and Nutrition (EPIC, N=4,731 IPLC cases) cohorts and pooled the SPLC risk estimates using random effects meta-analysis.Overall, 163 (2.3%) MEC cases developed a SPLC. Smoking pack-years (HR 1.18 per 10 pack-years; P<0.001) and smoking intensity (HR 1.30 per 10 cigarettes per day (CPD); P<0.001) were significantly associated with increased SPLC risk. Individuals who met the 2013 U.S. Preventive Services Task Force's (USPSTF) screening criteria at IPLC diagnosis also had an increased SPLC risk (HR 1.92; P<0.001). Validation studies with PLCO and EPIC showed consistent results. Meta-analysis yielded pooled HRs of 1.16 per 10 pack-years (Pmeta<0.001), 1.25 per 10 CPD (Pmeta<0.001), and 1.99 (Pmeta<0.001) for meeting the USPSTF criteria. In MEC, smoking cessation after IPLC diagnosis was associated with an 83% reduction in SPLC risk (HR 0.17; P<0.001).Tobacco smoking is a risk factor for SPLC. Smoking cessation after IPLC diagnosis may reduce the risk of SPLC. Additional strategies for SPLC surveillance and screening are warranted.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|x 0
|f POF IV
588 _ _ |a Dataset connected to DataCite, PubMed,
650 _ 7 |a screening
|2 Other
650 _ 7 |a second primary lung cancer
|2 Other
650 _ 7 |a smoking cessation
|2 Other
650 _ 7 |a surveillance
|2 Other
650 _ 7 |a tobacco smoking
|2 Other
700 1 _ |a Luo, Sophia J
|b 1
700 1 _ |a Gardner, Rebecca M
|b 2
700 1 _ |a Sanyal, Nilotpal
|b 3
700 1 _ |a Choi, Eunji
|b 4
700 1 _ |a Hickey, Thomas P
|b 5
700 1 _ |a Riley, Thomas L
|b 6
700 1 _ |a Huang, Wen-Yi
|b 7
700 1 _ |a Kurian, Allison W
|b 8
700 1 _ |a Leung, Ann N
|b 9
700 1 _ |a Wilkens, Lynne R
|b 10
700 1 _ |a Robbins, Hilary A
|b 11
700 1 _ |a Riboli, Elio
|b 12
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 13
|u dkfz
700 1 _ |a Tjønneland, Anne
|b 14
700 1 _ |a Vermeulen, Roel C H
|b 15
700 1 _ |a Panico, Salvatore
|b 16
700 1 _ |a Le Marchand, Loïc
|b 17
700 1 _ |a Amos, Christopher I
|b 18
700 1 _ |a Hung, Rayjean J
|b 19
700 1 _ |a Freedman, Neal D
|b 20
700 1 _ |a Johansson, Mattias
|b 21
700 1 _ |a Cheng, Iona
|b 22
700 1 _ |a Wakelee, Heather A
|b 23
700 1 _ |a Han, Summer S
|b 24
773 _ _ |a 10.1016/j.jtho.2021.02.024.
|0 PERI:(DE-600)2223437-8
|n 6
|p 968-979
|t Journal of thoracic oncology
|v 16
|y 2021
|x 1556-0864
909 C O |o oai:inrepo02.dkfz.de:167921
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2021-01-26
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J THORAC ONCOL : 2019
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-26
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J THORAC ONCOL : 2019
|d 2021-01-26
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21